Literature DB >> 33552054

Vitamin D3-Induced Tolerogenic Dendritic Cells Modulate the Transcriptomic Profile of T CD4+ Cells Towards a Functional Hyporesponsiveness.

Juan Navarro-Barriuso1,2, María José Mansilla1,2, Bibiana Quirant-Sánchez1,2, Aina Teniente-Serra1,2, Cristina Ramo-Tello3, Eva M Martínez-Cáceres1,2.   

Abstract

The use of autologous tolerogenic dendritic cells (tolDC) has become a promising alternative for the treatment of autoimmune diseases. Among the different strategies available, the use of vitamin D3 for the generation of tolDC (vitD3-tolDC) constitutes one of the most robust approaches due to their immune regulatory properties, which are currently being tested in clinical trials. However, the mechanisms that vitD3-tolDC trigger for the induction of tolerance remain elusive. For this reason, we performed a full phenotypical, functional, and transcriptomic characterization of T cells upon their interaction with autologous, antigen-specific vitD3-tolDC. We observed a strong antigen-specific reduction of T cell proliferation, combined with a decrease in the relative prevalence of TH1 subpopulations and IFN-γ production. The analysis of the transcriptomic profile of T CD4+ cells evidenced a significant down-modulation of genes involved in cell cycle and cell response to mainly pro-inflammatory immune-related stimuli, highlighting the role of JUNB gene as a potential biomarker of these processes. Consequently, our results show the induction of a strong antigen-specific hyporesponsiveness combined with a reduction on the TH1 immune profile of T cells upon their interaction with vitD3-tolDC, which manifests the regulatory properties of these cells and, therefore, their therapeutic potential in the clinic.
Copyright © 2021 Navarro-Barriuso, Mansilla, Quirant-Sánchez, Teniente-Serra, Ramo-Tello and Martínez-Cáceres.

Entities:  

Keywords:  T cells; antigen-specific response; immune tolerance; tolerogenic dendritic cells; transcriptomic study

Mesh:

Substances:

Year:  2021        PMID: 33552054      PMCID: PMC7856150          DOI: 10.3389/fimmu.2020.599623

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  38 in total

1.  Beneficial effect of tolerogenic dendritic cells pulsed with MOG autoantigen in experimental autoimmune encephalomyelitis.

Authors:  María José Mansilla; Carla Sellès-Moreno; Sara Fàbregas-Puig; Joan Amoedo; Juan Navarro-Barriuso; Aina Teniente-Serra; Laia Grau-López; Cristina Ramo-Tello; Eva M Martínez-Cáceres
Journal:  CNS Neurosci Ther       Date:  2014-11-18       Impact factor: 5.243

2.  Differential protein pathways in 1,25-dihydroxyvitamin d(3) and dexamethasone modulated tolerogenic human dendritic cells.

Authors:  Gabriela Bomfim Ferreira; Fleur S Kleijwegt; Etienne Waelkens; Kasper Lage; Tatjana Nikolic; Daniel Aaen Hansen; Christopher T Workman; Bart O Roep; Lut Overbergh; Chantal Mathieu
Journal:  J Proteome Res       Date:  2011-12-15       Impact factor: 4.466

Review 3.  The role of dendritic cells in autoimmunity.

Authors:  Dipyaman Ganguly; Stefan Haak; Vanja Sisirak; Boris Reizis
Journal:  Nat Rev Immunol       Date:  2013-07-05       Impact factor: 53.106

4.  Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1,25-dihydroxyvitamin D3.

Authors:  Giuseppe Penna; Andrea Roncari; Susana Amuchastegui; Kenn C Daniel; Emilio Berti; Marco Colonna; Luciano Adorini
Journal:  Blood       Date:  2005-07-19       Impact factor: 22.113

5.  Distinctive dendritic cell modulation by vitamin D(3) and glucocorticoid pathways.

Authors:  Nianzeng Xing; Monica L L Maldonado; Lori A Bachman; David J McKean; Rajiv Kumar; Matthew D Griffin
Journal:  Biochem Biophys Res Commun       Date:  2002-09-27       Impact factor: 3.575

6.  Therapy of type 1 diabetes with CD4(+)CD25(high)CD127-regulatory T cells prolongs survival of pancreatic islets - results of one year follow-up.

Authors:  Natalia Marek-Trzonkowska; Małgorzata Myśliwiec; Anita Dobyszuk; Marcelina Grabowska; Ilona Derkowska; Jolanta Juścińska; Radosław Owczuk; Agnieszka Szadkowska; Piotr Witkowski; Wojciech Młynarski; Przemysława Jarosz-Chobot; Artur Bossowski; Janusz Siebert; Piotr Trzonkowski
Journal:  Clin Immunol       Date:  2014-04-01       Impact factor: 3.969

7.  JunB promotes Th17 cell identity and restrains alternative CD4+ T-cell programs during inflammation.

Authors:  Tiffany M Carr; Joshua D Wheaton; Geoffrey M Houtz; Maria Ciofani
Journal:  Nat Commun       Date:  2017-08-21       Impact factor: 14.919

8.  MAP7 and MUCL1 Are Biomarkers of Vitamin D3-Induced Tolerogenic Dendritic Cells in Multiple Sclerosis Patients.

Authors:  Juan Navarro-Barriuso; María José Mansilla; Bibiana Quirant-Sánchez; Alicia Ardiaca-Martínez; Aina Teniente-Serra; Silvia Presas-Rodríguez; Anja Ten Brinke; Cristina Ramo-Tello; Eva M Martínez-Cáceres
Journal:  Front Immunol       Date:  2019-06-19       Impact factor: 7.561

9.  Dexamethasone and Monophosphoryl Lipid A-Modulated Dendritic Cells Promote Antigen-Specific Tolerogenic Properties on Naive and Memory CD4+ T Cells.

Authors:  Jaxaira Maggi; Katina Schinnerling; Bárbara Pesce; Catharien M Hilkens; Diego Catalán; Juan C Aguillón
Journal:  Front Immunol       Date:  2016-09-19       Impact factor: 7.561

10.  Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis.

Authors:  G M Bell; A E Anderson; J Diboll; R Reece; O Eltherington; R A Harry; T Fouweather; C MacDonald; T Chadwick; E McColl; J Dunn; A M Dickinson; C M U Hilkens; John D Isaacs
Journal:  Ann Rheum Dis       Date:  2016-04-26       Impact factor: 19.103

View more
  2 in total

1.  Analysis of the Seasonal Fluctuation of γδ T Cells and Its Potential Relation with Vitamin D3.

Authors:  Birthe Bernicke; Nils Engelbogen; Katharina Klein; Jeanette Franzenburg; Christoph Borzikowsky; Christian Peters; Ottmar Janssen; Ralf Junker; Ruben Serrano; Dieter Kabelitz
Journal:  Cells       Date:  2022-04-26       Impact factor: 7.666

Review 2.  Paving the way towards an effective treatment for multiple sclerosis: advances in cell therapy.

Authors:  M J Mansilla; S Presas-Rodríguez; A Teniente-Serra; I González-Larreategui; B Quirant-Sánchez; F Fondelli; N Djedovic; D Iwaszkiewicz-Grześ; K Chwojnicki; Đ Miljković; P Trzonkowski; C Ramo-Tello; E M Martínez-Cáceres
Journal:  Cell Mol Immunol       Date:  2021-05-06       Impact factor: 22.096

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.